17 u ma R e e t w % m e o e e b e Primary Strategic Priority Source Strategic Priority One: Effectively PROMPT NOTIFIABLE OUTBREAK DISEASE manage and strengthen Australia’s emergency animal disease response arrangements through successful partnerships with Members Strategic Priority Two: Enhance the EAD preparedness and response capability of AHA and its Members 58% 37% 5% 17 uals mal process for variations and amendments to the EADRA are in progress RA published three months early eved – Members endorsed additional resources, and mechanisms have established ready for implementation in 2017-18 eved – mechanisms identified ready for implementation in 2017-18 tional activities: w baselines established – 30% AUSVETPLAN updated in past 5 years % minor reviews completed in less than 2 years; no major reviews mpleted eved – information mapping consultancy completed that identifies onse function needs eved – templates updated eved – banks are available for use and verified annually by manufacturer 80% DSMs & RPBs in new templates Enterprise manual templates updated Banks are available for use with appropriate strains and quantities of antigens Anthrax consultation re future requirements (e.g. number of doses) ber survey: 4.1 4.0 or above (out of 5) FMD – new contractual arrangements and vaccine bank in place and ready for use Anthrax – to be advised following consultation with funding parties 4.0 or above (out of 5) How did we track? 17/18 Targets New version published October 2017; Recommitment by all Signatories following 3rd 5 year review 50% updated in past 5 years 80% of disease strategy manuals (DSMs) & response policy briefs (RPBs) annually monitored 2020 Targets New version published October 2020 100% updated in past 5 years 100% of DSMs & RPBs annually monitored 100% enterprise manuals updated DETECTION & EFFECTIVE EAD RESPONSE IN PLACE 19 M&E INDICATORS* 100% DSMs & RPBs in new templates eved - supply and delivery exercise in preparation Supply chain exercise conducted Exercise findings improve processes for FMD vaccine delivery Anthrax - Negotiate extension of supply agreement under clause 3 FMD – new contractual arrangements and vaccine bank in place and ready for use Anthrax – to be advised following consultation with funding parties *AHA’s M&E indicators are used to measure the company’s progress towards outcomes in key business areas, which are directly aligned with AHA’s broader strategic priorities. ANNUAL REPORT 2016-17 27
32 Publizr Home